Informations

In recent years, advancements in Hematopoietic Cell Transplantation (HCT) technology have significantly improved long-term survival rates, with about 80% of patients achieving disease-free survival for more than two years post-transplant. However, as time progresses, long-term survivors of transplantation still face the risk of chronic complications, which directly impact their quality of life and outcomes post-transplant.…

Mucormycosis is a group of rare and highly invasive fungal diseases, and its combination with allogeneic hematopoietic stem cell transplantation increases the difficulty of diagnosis and treatment. Previously, the difficulty in rapidly diagnosing mucormycosis often led to poor prognosis in patients with transplantation-associated mucormycosis. At the 50th European Society for Blood and Marrow Transplantation (EBMT)…

Acute myeloid leukemia (AML) is a common and aggressive hematological malignancy with poor prognosis. For patients with relapsed/refractory (R/R) AML, allogeneic hematopoietic stem cell transplantation (allo-SCT) is one of the important treatment options. However, patients with R/R AML often face primary or secondary drug resistance and limited treatment options due to complications and physical condition,…

Relapsed and refractory acute myeloid leukemia (AML) presents one of the most formidable challenges in oncology, lacking a unified and efficient treatment strategy. Dr. Johannes Schetelig, Head of the Cell Therapy Unit at the Technical University of Dresden and Chair of the Clinical Trials Unit within the DKMS, offers invaluable insights into the complexities and…